

Q2 2019 Payment Limit Report for Ophthalmology

CMS has released the Q2 2019 drug pricing files for both average sales price (ASP) and not otherwise classified (NOC) drugs. These changes are effective **April 1, 2019** and will remain in effect until either a correction or the next scheduled update is made by CMS.

The data used for the Q2 2019 reimbursement files is based on the Q4 2018 sales data submitted to CMS by drug manufacturers. We encourage you to review the revised drug payment limit files, including reimbursement allowables on NOC drugs, on the [CMS Website](#).

2% Sequestration Cut to Medicare Reimbursements

Due to sequestration, a 2% cut to Medicare payments has been applied to providers with services dates on or after April 1, 2013. As a result, the effective rate for office-administered drugs will be ASP+4.3%. However, the underlying allowable will remain at ASP+6%, which may be a basis for private payer reimbursement rates. We encourage you to check with your private payers to understand their allowable rates for physician fee schedule Part B drugs.

Drug	HCPCS Code	Billing Unit	Q1 2019 ASP+6%	Q2 2019 ASP+6%	% Change
Aflibercept (EYLEA®)	J0178	1 MG	\$963.54	\$960.20	-0.35%
Alteplase recombinant (ACTIVASE®)	J2997	1 MG	\$87.75	\$87.68	-0.08%
Bevacizumab (AVASTIN®)	J9035	10 MG	\$81.18	\$81.22	0.05%
Dexamethasone intravitreal implant	J1100	1 MG	\$0.11	\$0.10	-10.19%
Fluocinol acet intravit imp (ILUVIEN®)	J7313	.01 MG	\$490.66	\$490.81	0.04%
Methylprednisolone Acetate Injection	J2920	40 MG	\$4.87	\$4.46	-8.38%
Methylprednisolone Acetate Injection	J2930	125 MG	\$6.93	\$6.36	-8.19%
Mitomycin	J9280	5 MG	\$125.07	\$115.92	-7.33%
Ocriplasmin (JETREA®)	J7316	.125 MG	\$1,046.93	\$1,042.28	-0.45%
Pegaptanib sodium (MACUGEN®)	J2503	0.3 MG	\$716.48	\$713.50	-0.42%
Ranibizumab (LUCENTIS®)	J2778	0.1 MG	\$363.98	\$364.15	0.05%